Skip to main content
. Author manuscript; available in PMC: 2013 Oct 3.
Published in final edited form as: Pharm Res. 2010 Dec 4;28(4):776–787. doi: 10.1007/s11095-010-0330-4

Fig. 2.

Fig. 2

CPT-SSM-VIP exerts anti-CIA action at lower CPT doses. CPT dose in all drug groups was 0.1 mg/kg. (a) CIA mice paws at the end of the study relative to normal unimmunized DBA/1 mice paw thickness. (b) Clinical arthritis scores at the end of the study relative to normal unimmunized DBA/1 mice at the end of the study. Results are expressed as mean ± S.E. M. (6 mice/group). * p<0.05 CPT-SSM versus CPT-SSM-VIP, † p<0.05 CPT versus CPT-SSM-VIP, ‡ p<0.05 versus normal mice.